Top of page Skip navigation

    Only a few options remain for this leading conference


Tuesday 28 November

19.00 - 21.00

Join us at Cardiff Castle for an informal evening of networking ahead of the conference.  Ideal for those arriving early in Cardiff. The evening is kindly supported by Merck.

Places are limited.

Wednesday 29 November

09.15 - 10.00

Refreshments, networking, exhibition and partnering

10.00 - 10.10


Dr Nigel Darby
Executive Advisor, GE Healthcare Life Sciences

10.10 - 10.20

BIA update

Steve Bates OBE
Chief Executive Officer, BIA

10.20 - 11.30

Post Industrial Strategy - growing UK biotech

Steve Bates OBE
Chief Executive Officer, BIA


Building something great -UK's global bioscience cluster report

John Hodgson
Executive Editor, Pharma, Informa

Advanced therapies - where we are and what we need to do to anchor commercial scale here in the UK
Ian McCubbin
 Independent Pharmaceutical Professional, Keirbridge

o Pisani
Partner, Strategy&, PwC

The Industrial Strategy Challenge Fund - new opportunities for growth
Mike will provide an update on opportunities for support of companies in the sector by Innovate UK and the new opportunities made possible by the £181 million of new funds made available through the Industrial Strategy Challenge Fund and the Government’s Industrial Strategy.

Dr Mike Sullivan
Interim Challenge Director, Medicines Manufacturing, Innovate UK

11.30 - 12.00

 Refreshment, networking, exhibition, poster display and partnering

12.00 - 12.15

Richard Wilson Impact Award

Presented by

Dr Stephen Ward
Chief Operating Officer, Cell and Gene Therapy Catapult, and Chair of BIA Manufacturing Advisory Committee

12.15 - 13.15

Young Researchers poster flash presentations

In this fast-moving session kindly supported by Pall Life Sciences, we hear from 20 early career researchers as they give a snapshot of their work and poster which is on display in the main exhibition area.

Dr Peter Levison
Senior Marketing Director - Downstream Processing, Pall Life Sciences 

13.15 - 14.30

Lunch, networking, exhibition, poster display and partnering

14.30 - 16.00


14.30 - 16.00

Purification of next generation medicines

The bioindustry is at a nexus between traditional recombinant protein production and supporting next generation biologic based medicines.  Do the manufacturing paradigms and technologies, developed in the 20th century for IgGs, still hold true for innovative therapies in the 21st? This workshop will focus on some new areas of bioprocess research from the latest chromatography resins to insights of novel molecule production.     

Chair: Dr Richard Turner
Director of Purification Process Sciences, MedImmune (A member of the Astrazeneca Group) 


Rapid Process Development of Viral Vector-based products for Cell and Gene Therapy Applications: Challenges and Opportunities.

Adeno-associated virus (AAV) vectors are currently the leading candidates for viral-based gene therapy because of their broad tissue tropism, non-pathogenic nature and low immunogenicity. AAV-based products are changing the lives of patients receiving treatment as part of early stage clinical trials, as well as being approved for treatment of lipoprotein lipase deficiency in Europe. This workshop presentation will discuss the complexity and challenges associated with rapid process development, required for robust clinical (and commercial) manufacturing for AAV based viral vectors to support the cell and gene therapy sector.

Dr Daniel Smith
Chief Scientific Officer, Cobra Biologics


Supporting the changing bioprocessing landscape

The underlying bioprocessing landscape is changing with new approaches to existing molecular types such as mAbs being required and completely new, complex non platform therapeutics in development. Demands for mAbs as therapies continues to show strong growth (10% CAGR), with 70 mAb expected to be approved by 2020. There is thus continuing interest in new approaches to mAb processing to impact manufacturing efficiency, cost of goods and consistency in product quality.

Reflecting increasing fundamental understanding of disease processes, a growing number of new therapeutics are under development and evaluation. These diverse types of molecular entity range from bispecific antibodies through viral vectors to whole cell therapies and at present there is a lack of manufacturing platforms and all provide individual bioprocessing challenges. The National Biologics Manufacturing Centre at CPI exists to support organisations with a UK presence to bridge the developability gap between discovery and commercialisation. Using some examples from the current project portfolio some approaches to support bioprocess development will be discussed.

Dr John Liddell
Senior Scientific Advisor, CPI NBMC


Primary capture purification offering new single-use bioprocessing opportunities

Purification productivities of 100’s g/L/h can be achieved by utilising the high flowrate and high capacities of nanofibres. This means for an equivalent bioreactor harvest, a significantly smaller nanofibre adsorbent cartridge can be used if rapid cycling is employed. The use of smaller, pre-packed, plug and play units, for preparative protein capture improves process flexibility in an effort to maximise facility productivity.

Dr Oliver Hardick
Chief Executive Officer, Puridify


Development of the next generation protein A chromatography resin

Protein A based affinity chromatography is well-established as the capture step in monoclonal antibody purification processes due to the high degree of selectivity and purity obtained. Increasing titres and a demand for better cleaning in place and sanitization procedures calls for protein A chromatography resins with improved features such as higher dynamic binding capacity and better alkaline stability. This presentation will highlight the development and evaluation of a novel protein A chromatography resin. Binding capacity data, alkaline stability and resin performance, in terms of yield and purity, will also be presented.

Dr Kajsa Stridsberg-Friden
Senior Project Manager, Downstream Processing, GE Healthcare Life Sciences


Adaptive manufacturing

Adaptive manufacturing? Conceptually this envisages a system in which the parts of a process – for us the manufacture of a successful product – can be integrated with the incorporation of greater automation, in which control processes respond to real-time measurement information about process events. Again, in concept, this should allow continuous adaptation and control to maximise the predictability of achieving product quality and consistency. That’s the theory but what is the reality for the bioprocessing sector? Are we able to learn the lessons from other sectors and develop the innovative automated solutions required? This will be the focus of the workshop. We do not know if we have answers but we hope that the presentations will reflect current thinking and stimulate further sector-wide discussions.

Chair: Professor Alan Dickson, Professor of Biotechnology, The University of Manchester


Is Adaptive Processing Adaptable Enough?

As the range of products being developed as biopharmaceuticals expands beyond traditional proteins to include viral vectors, cell therapies, mRNA and more and products move from high volume blockbusters to more focused and personalised therapies, can real time analytics and process control hope to keep up?

Dr Andy Topping
Chief Scientific Officer, FUJIFILM Diosynth Biotechnologies


Cell therapy manufacture – The role of adaptive control

This presentation will examine the role that process analytical technologies (PAT) and multivariate analysis have in supporting the move toward reactive, information driven manufacturing processes.

Dr Damian Marshall
Head of Analytical Development, Cell and Gene Therapy Catapult


DOE, machine learning and automation: Demonstrating Antha, a powerful platform for biology

Deceptively simple from the lab user's perspective, the Antha software platform integrates and controls lab devices and automation (across models and manufacturers), enabling highly complex experimentation to be carried out with ease. Its applications span research and development, bioprocess development and optimisation as well as analytics and quality management. See a demonstration of the Antha software and discuss how it can be applied in adaptive manufacturing.

Dr Markus Gershater
Chief Scientific Officer, Synthace


Adaptive process control for next generation biologics and biomanufacturing of the future

Biologics are becoming increasingly complex in terms of therapeutic properties and the conditions required to manufacture them. The diversifying pipelines within the biologics industry present a significant challenge during process development and through into biomanufacturing. A game changing solution to such challenges is the adoption of adaptive process control techniques. A review of the state-of-the-art, including a  number of case studies, will be presented giving insight into the use of adaptive process control during upstream process development and manufacturing.

Dr Sam Watts

Technical Business Development Officer & Co-Founder, Stratophase

Medicines Manufacturing Industry Partnership (MMIP)
Leaders in key UK manufacturing sites will discuss the attractiveness of the UK for investment in medicines manufacturing, utilising what we do well but also identifying what we need to work on, through MMIP, to ensure continued growth of the sector.

Andy Evans
Head of Macclesfield Site, AstraZeneca

Steve Bagshaw
Chief Executive Officer, FUJIFILM Diosynth Biotechnologies

Dr Crawford Brown
Senior Vice President Biologics R&D, Allergan

Dr Jim Faulkner
Senior Vice President and Head of Product Delivery, Autolus

Dr James Miskin
Chief Technical Officer, Oxford BioMedica

16.00 - 16.30

Refreshments, networking, exhibition and partnering

16.30 - 17.00

Outputs from workshops

In this session, we will hear from workshop chairs on the feedback as they present back to conference attendees

17.00 - 17.45

Peter Dunnill Award Presentation and Lecture

Hindsight is a powerful teacher or "Moch is deiseil ‘son an t-slighe"

The bioprocessing sector is a truly amazing community in which personal contacts between great people has benefited the whole sector.  Excellent fundamental science has enabled astonishing changes to the therapeutic landscape.   Alan will deliver a personal reflection on the challenges, successes and enjoyment of working as part of bioprocessing community over the past 25 years.

Professor Alan Dickson
Professor of Biotechnology, University of Manchester

17.45 - 17.50

Summary and close of day one

19.00 - 23.00

Drinks reception and conference dinner

Conference attendees, exhibitors and supporters are invited to join us at the National Museum of Cardiff  for an informal networking drinks reception while enjoying the galleries, followed by evening dinner in the Grand Hall

08.45 - 14.30

Thursday 30 November

08.45 - 09.15

Refreshments, networking, exhibition, poster display and partnering

09.15 - 10.45

Application of platform technologies in developing vaccines for emerging diseases, biological threats and unmet needs

Dr Steve Chatfield
Chairman, Prokarium

The spy toolbox for plug-and-display vaccination
We have generated protein superglues from bacteria to accelerate the production of vaccines. Using plug-and-display technology, antigens from viruses, bacteria or self-proteins are irreversibly linked on to virus-like particles. This modular production generates potent antibody responses and can enhance the preparation against emerging pandemics.

Dr Mark Howarth
Co-Founder, SpyBiotech

Vaxonella - Salmonella-vectored oral vaccine delivery

Prokarium’s Vaxonella platform uses advanced genetic and formulation technologies to deliver vaccines orally using safe strains of Salmonella. These vaccine vectors have been evaluated in several clinical trials and are manufactured using a simple process that imparts enhanced thermostability, which will enable ambient temperature distribution to end-users. New data will be presented on the development of a plague vaccine using Vaxonella.

Dr Rocky Cranenburgh
Chief Scientific Officer, Prokarium


Oral vaccination - a pharmaceutical approach

An encapsulation technology which brings together antigens, immunostimulants, oils and polysaccharides all in the same vehicle is an ideal candidate for an oral vaccine.  Proof of principle and demonstration of efficacy will be shown here for important diseases such as avian 'flu, infantile diarrhoea and plague

Dr Roger New
Proxima Concepts 


10.45 - 11.15

Refreshments, networking, exhibition, poster display and partnering

11.15 - 13.15

Delivering cell and gene therapies to patients

With the approval of several high impact cell and gene therapies this year, the life changing power of these advanced therapies is now becoming a reality. Listen to global experts as they unpick the clinical and manufacturing journey over the last decade and offer a vision for the next ten years

Dr Stephen Ward
Chief Operating Officer, Cell and Gene Therapy Catapult and Chair of BIA Manufacturing Advisory Committee

Cellular therapeutics - a decade of experience in T cell multi-product manufacturing in oncology

T cell therapy of cancer has moved from a scientific theory to a medicine, recommended for marketing approval, for patient treatment within two decades. In order for these treatments to become widely available manufacturing needs to move from the small scale, highly complex processes, to industrialised, high throughput. This will also require specialised training for clinicians to allow hospital roll-out. An exciting time ahead challenging the infrastructure, legislation and a new era in the patient/pharma relationship.

Dr Ryan Guest
Director of Cell Production and Co-founder,Cellular Therapeutics

Delivery of Adoptive Immunotherapy Medicines to Patients- Building and Establishing an Effective Supply Chain
A number of adoptive immunotherapies are now preparing for market approval but challenges still exist to ensure patient access to these ground-breaking medicines. Innovative solutions and approaches are required across manufacturing, supply chain and the regulatory framework

Dr Bo Kara
Head Process Development, Cell & Gene Therapy Platform CMC, GlaxoSmithKline

Haemophilia gene therapy

The first trial to provide clear evidence of efficacy after adeno-associated virus vector mediated gene transfer was reported by our group in 2011 in patients with haemophilia B. Since then several groups have reported success in both haemophilia A and B. An update on the progress made in this field in the last 6 years will be presented.   

Professor Amit Nathwani
Head of Haematology, UCL Royal Free Hospital 

Manufacturing cell and gene therapies:  challenges and opportunities for this new class of therapies

Advanced therapies bring clinical practice and pharmaceutical development closer than ever. Cell and gene therapies introduce significant complexity into manufacturing and supply chains including custody management and cold-chain distribution. Automation and new manufacturing paradigms will be needed to match supply to demand and to help assure a supply of these treatments in the future

Dr Phil Vanek
General Manager, Cell Therapy Technologies Strategy, GE Healthcare

13.15 - 13.20

Announcement of Early Career Researchers Poster Prize Competition Winner

13.20 - 13.30

Closing remarks

Nick Gardiner
Chief Operating Officer, BioIndustry Association

13.30 - 14.30

Lunch, networking, exhibition and partnering